Sugi Predict

Sugi Predict / Compounds / SCHEMBL3489714

SCHEMBL3489714

SCHEMBL3489714

COc1ccccc1-c1nn(COCC[Si](C)(C)C)c2ncc(-c3cc(C)c(N)c(C(=O)O)c3)cc12

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 1/20 0.36
▸ DHODH Q02127 2/20 0.35
▸ NEK2 P51955 1/20 0.35
▸ CHRNA7 P36544 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ EGLN1 Q9GZT9 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ AXL P30530 1/20 0.33
▸ TYRO3 Q06418 1/20 0.33
▸ MERTK Q12866 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ ALOX5AP P20292 1/20 0.33
▸ FEN1 P39748 1/20 0.33
▸ CAMKK2 Q96RR4 1/20 0.33
▸ MAP3K11 Q16584 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3490245 0.92 FEN1 (0.39) MAP4K1DHODHEGLN1AXLTYRO3
SCHEMBL3489195 0.86 EIF4E (0.38) MAP4K1DHODHEGLN1
SCHEMBL3488690 0.83 MAP4K1 (0.56) MAP4K1AXLTYRO3MERTKALOX5AP
SCHEMBL3490132 0.83 MERTK (0.37) MAP4K1DHODHMERTK
SCHEMBL3489403 0.83 CHEK1 (0.38) MAP4K1MAPTKMT2AAXLTYRO3
SCHEMBL3488256 0.82 ABL1 (0.43) MAP4K1EGLN1MAP3K11
SCHEMBL3489488 0.81 MAP4K1 (0.46) MAP4K1MAPTKMT2AAXLTYRO3
SCHEMBL4359217 0.81 FYN (0.37) MAP4K1EGLN1AXL
SCHEMBL3488599 0.81 TP53 (0.39) EGLN1MAP3K11
SCHEMBL3490227 0.81 MAP4K1 (0.42) MAP4K1MAPTAXLTYRO3MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268994-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2012-09-18 — — US disclosed
US-8268994-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2012-09-18 — — US disclosed
US-20100036118-A1 Fused Ring Heterocycle Kinase Modulators SGX PHARMACEUTICALS, INC. 2010-02-11 — — US disclosed
US-20100036118-A1 Fused Ring Heterocycle Kinase Modulators SGX PHARMACEUTICALS, INC. 2010-02-11 — — US disclosed
EP-2134179-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-12-23 — — EP disclosed
US-7626021-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-12-01 — — US disclosed
US-7626021-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-12-01 — — US disclosed
WO-2008124850-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 — — WO disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 — — US disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, TTK, MAP3K19 MAP4K1 19/4885DHODH 1796/4885NEK2 164/4885
US-20100036118-A1 Fused Ring Heterocycle Kinase Modulators MAP3K20, TTK, MAP3K19 MAP4K1 19/4885DHODH 1796/4885NEK2 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.